# Optimized Treatment of Peginterferon Alfa 2a in Treatment Experienced Patients With HBV Related Liver Fibrosis

> **NCT03957629** · NA · UNKNOWN · sponsor: **Third Affiliated Hospital, Sun Yat-Sen University** · enrollment: 186 (estimated)

## Conditions studied

- Hepatitis B
- Liver Fibrosis

## Interventions

- **DRUG:** Tenofovir Disoproxil Fumarate
- **DRUG:** PEG-Interferon alfa 2a

## Key facts

- **NCT ID:** NCT03957629
- **Lead sponsor:** Third Affiliated Hospital, Sun Yat-Sen University
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-11-06
- **Primary completion:** 2021-07-30
- **Final completion:** 2023-07-30
- **Target enrollment:** 186 (ESTIMATED)
- **Last updated:** 2020-01-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03957629

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03957629, "Optimized Treatment of Peginterferon Alfa 2a in Treatment Experienced Patients With HBV Related Liver Fibrosis". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT03957629. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*